Previous 10 | Next 10 |
Theratechnologies (THTX) announces results from two posters highlighting positive patient experience with Trogarzo. The poster included findings from 30 Trogarzo (ibalizumab-uiyk) patients to assess real-world patient experience and acceptance of IV administration.The survey found that 1...
100% of patients expressed satisfaction with treatment experience 98% compliance observed with Trogarzo ® MONTREAL, May 20, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical compan...
MONTREAL, May 18, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer wil...
Theratechnologies Inc. (THTX) Q1 2021 Earnings Conference Call April 14, 2021, 8:30 AM ET Company Participants Denis Boucher - Vice President, Communications and Corporate Affairs Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chief Financial ...
MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer w...
MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the first quar...
MONTREAL, April 10, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new in vivo preclinical data were presented at the...
The first quarter of 2021 is over, and it has been radically different from the first quarter last year, primarily because last time, the quarter ended with the market struggling to get up from the depths of the pandemic-driven crash. 2021’s first quarter is all about recovery and gr...
MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the additi...
Theratechnologies (THTX) announces that the first patient received a dose of TH1902, its lead peptide-drug conjugate ((PDC)) for the treatment of sortilin positive (SORT1+) solid tumors. The Phase 1 trial of TH1902 includes a dose-escalating part to evaluate the safety, pharmacokinetics, maxi...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...